SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding a capital raise. | 28/10/2022 |
The company releases an Investor Presentation. | 28/10/2022 |
The company releases a notice of proposed issue of securities. | 28/10/2022 |
Single tranche share Placement conducted following further strong clinical trial results at 20 weeks for NTI164 in children with Autism Spectrum Disorder. Binding commitments for a $9.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors. Capital raised fully funds multiple Phase I/II clinical trials in PANDAS/PANS and cerebral palsy, a large Phase II/III trial in ASD and various US FDA initiatives. | 28/10/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a capital raise. | 27/10/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 08/07/2022 |
93% of patients showed symptom improvement relating to the severity of illness after 28 days of daily treatment with NTI164. 64% of patients had a global improvement of "much improved'". 29% of patients had a global improvement of "minimally improved". 7% of patients had "no change". Two patients recorded a Marked Therapeutic Index Score of 2 = vast improvement meaning: complete or near remission of all symptoms. Ten patients recorded a Moderate Therapeutic Index Score of 5 & 6 = representing "Decided improvement" "“ Partial remission of symptoms. The average rating for the severity of illness at baseline was 4.4. This was reduced to 3.6 after 28 days of NTI164 treatment. NTI164 was well-tolerated "“ No serious adverse events were recorded across all doses (5, 10, 15 and 20 mg/kg). No changes were noted in blood analysis or liver function tests. The study has been granted HREC approval to continue for a further 54 weeks due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians and their recent request for no "washout" period. Safety and efficacy assessments will continue. ï‚· The Company is in discussions with the US FDA regarding a pre-IND application scheduled for 2022. ï‚· Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including weight gain, sedation and hormonal imbalance. Given that NTI164 was welltolerated without weight gain or sedation, NTI164 shows promise compared to these treatments . Recently completed and published paediatric ASD studies utilising CBD and/or THC do not show any statistical efficacy and had minimal effects after three plus months and (with a THC component) had "˜sedation' as a significant side effect2,3. NTI164 measures favourably when compared to these treatments. The results open up opportunities for a potential treatment pathways outside of ASD including a wide range of neurological disorders such as Attention Deficit Hyperactivity Disorder ("ADHD"), Multiple Sclerosis, Motor Neuron Disease, Rett's Syndrome, Concussion and Cerebral Palsy. Conference Call with CEO, Dr Alexandra Andrews to be held at 11am WST today "“ details to follow. | 08/07/2022 |
The company wishes that its voluntary suspension remain in place until such time as the announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder is released to the market, or until the commmencement of trade on 8 July 2022. | 07/07/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 06/07/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by NTI of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 30/11/2020 |
DOLCE/NTI leads indicate significant increased potency in repairing brain cells when compared to CBD alone. These results have been achieved using 1/5th the dose of CBD alone. DOLCE/NTI leads found to exhibit novel modes of action critical in the treatment and management of Alzheimer's, Huntington's Disease, Multiple Sclerosis and other neurological disorders. DOLCE/NTI leads contains minimal THC (<0.3%) which may result in less onerous regulatory pathway towards commercialisation. Final In-vitro results expected next month. Conference call to be held at 11am AWST today. | 30/11/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 27/11/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following receipt of a response to ASX's Price and Volume Query. | 01/05/2020 |
The company issues a Response to ASX Price and Volume Query. | 01/05/2020 |
The company lodges its Quarterly Report and Appendix 4C. | 29/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Monday 4th May 2020. | 28/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Tuesday 28th April 2020. | 20/04/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a response to a price query. | 14/04/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by the Company of an announcement regarding a capital raising. | 16/10/2017 |
The company has successfully completed a well oversubscribed A$4 million placement of new shares to drive the company's ongoing commercialisation of the Mente Autism device. | 16/10/2017 |
The securities of Neurotech International Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement. | 12/10/2017 |
listed entity carried for record purposes only | 04/11/2016 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 03/12/2024 | Max Johnston | 200,000 | $0.066 | $13,275.00 |
| 29/01/2024 | Thomas Duthy | 340,000 | $0.091 | $30,820.00 |
| 02/08/2022 | Gerald Quigley | 277,777 | $0.090 | $25,000.00 |
| 14/07/2021 | Krista Bates | 180,000 | $0.056 | $10,044.00 |
| 14/07/2021 | Allan Cripps | 180,000 | $0.056 | $10,018.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Mark Davies | Non Exec Chairman, Independent Director | 16/04/2019 |
| Anthony Filippis | Managing Director, CEO | 01/02/2025 |
| Alexandra Andrews | COO | 08/03/2022 |
| Richard Small | CFO, COO | 04/11/2016 |
| Max Johnston | Non Exec Director | 19/04/2024 |
| Gerald Quigley | Non Exec Director | 07/07/2022 |
| Alessandra Gauvin | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
